Cogent Biosciences
COGT
47 hedge funds and large institutions have $62.8M invested in Cogent Biosciences in 2018 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 22 increasing their positions, 9 reducing their positions, and 11 closing their positions.
144% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 9
0.91% less ownership
Funds ownership: 12.82% → 11.9% (-0.91%)
9% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 11
2% less funds holding
Funds holding: 48 → 47 (-1)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
60% less capital invested
Capital invested by funds: $158M → $62.8M (-$94.9M)
Top Buyers
| 1 |
BlackRock
New York
|
+$8.35M |
| 2 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$1.5M |
| 3 |
CI
Cowen Inc
New York
|
+$1.24M |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$1M |
| 5 |
Two Sigma Investments
New York
|
+$949K |
Top Sellers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$10.8M |
| 2 |
Jennison Associates
New York
|
-$9.17M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$2.72M |
| 4 |
Fidelity International
Hamilton,
Bermuda
|
-$2.36M |
| 5 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$803K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Millennium Management
New York
| – | -$230K | -5,587 | Closed |
|
52
Squarepoint
New York
| – | -$200K | -4,850 | Closed |
|
53
Jane Street
New York
| – | -$150K | -3,630 | Closed |
|
54
UBS Group
Zurich,
Switzerland
| – | -$87K | -2,109 | Closed |
|
55
Barclays
London,
United Kingdom
| – | -$65K | -1,587 | Closed |
|
|
CCA
56
Catalyst Capital Advisors
Huntington,
New York
| – | -$6K | -149 | Closed |
|
57
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$2K | -42 | Closed |
|
COGT Hedge Fund Activity: Q4 2018 in Review
47 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Cogent Biosciences (COGT) for Q4 2018, worth a combined $62.8M — down 60% from $158M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of COGT and 10 opened new positions — a net loss of 1 holder — while 9 trimmed existing stakes and 22 added.
The largest buyer was BlackRock, adding an estimated $8.35M. The largest seller was Fidelity Investments, cutting an estimated $10.8M.
- 47 institutional investors held Cogent Biosciences (COGT) as of Q4 2018, down from 48 in Q3 2018.
- Funds reported $62.8M of Cogent Biosciences stock for Q4 2018, down 60% quarter-over-quarter.
- 10 funds opened new Cogent Biosciences positions in Q4 2018 and 11 closed out, a net change of -1 holder.
- The largest Cogent Biosciences buyer in Q4 2018 was BlackRock, an estimated $8.35M added.
- The largest Cogent Biosciences seller in Q4 2018 was Fidelity Investments, an estimated $10.8M sold.
Based on aggregated 13F filings for Q4 2018.